David Sable MD directs healthcare and life science investing for the Special Situations Funds and is portfolio manager of the Special Situations Life Sciences Fund. After graduating from the Wharton School and the University of Pennsylvania School of Medicine, he trained in obstetrics and gynecology at New York Hospital - Cornell Medical Center, and in reproductive endocrinology at the Brigham and Women's Hospital. He co-founded and served as director of the Institute for Reproductive Medicine and Science at Saint Barnabas Medical Center in New Jersey, and was founder and CEO of Assisted Reproductive Medical Technologies, a private company that was acquired in 1999.
After leaving clinical medicine, Dr. Sable managed a proprietary healthcare portfolio at Deutsche Bank before joining the Special Situations Funds. Dr. Sable is an adjunct in the department of biology at Columbia University, and teaches “Entrepreneurship in Biotechnology” at Columbia’s Graduate School of Arts and Sciences. He has lectured on healthcare investing, policy, and biotechnology business development at the Wharton School, NYU, Rockefeller University and Rutgers; has delivered keynote addresses to the American Fertility Society, the Texas Fertility Society and the Mexican Fertility Society; and appeared on the CBS Morning News, ABC World News Tonight, NY1 News and PBS’ Nova. He serves on the board of directors of Hamilton Thorne Ltd and for the nonprofit organization Resolve, and is a member of the clinical advisory board for Ovascience, a Massachusetts-based public company developing advanced treatments for infertility. In addition to his academic publications, he has written for the Newark Star-Ledger, Yoga Journal, Xconomy, Genetic Engineering and Biotechnology News, Wharton Magazine, the Columbia Spectator, and writes the “…and other secrets of the buy side” and the "...and other things I learned as an IVF doc" blogs for Forbes Magazine.
Website for Biotechnology 4180 at Columbia: www.biot4180.weebly.com
My LinkedIn page is here
My twitter profile is here
My blog page at Forbes is here: http://www.forbes.com/sites/davidsable/
1986 M.D. University of Pennsylvania
1981 B.S. Wharton School, University of Pennsylvania
Asset Management Positions:
2004-2005 Healthcare Analyst, Equitech Group, Deutsche Bank, New York
2005-current Portfolio Manager, Special Situations Life Sciences Fund, New York
Corporate Directorships and Advisory Boards
2010-2014, 2017- Hamilton Thorne Ltd. (HTL.CN TSX-V) Beverly, MA.
2011-current Ovascience, Boston, MA. Scientific advisory board.
2009-2014 Genenews Ltd. (GEN.CN TSX), Toronto, Ontario. Audit comm.
2012-current Resolve, the National Infertility Association, Mclean, VA.
1990-1992 Instructor in Obstetrics and Gynecology, Harvard Medical School, Boston, MA
2011- Lecturer, Department of Biological Sciences, Columbia University, New York, NY
1986-1989 Assistant Obstetrician and Gynecologist, New York Hospital, New York, NY
1989-1990 Obstetrician and Gynecologist, New York Hospital
1990-1992 Obstetrician and Gynecologist, Brigham and Women's Hospital, Boston, MA
1992-2004 Obstetrician and Gynecologist, Saint Barnabas Medical Center, Livingston, NJ
1992-1998 Associate Director, Reproductive Endocrinology and Infertility, Saint Barnabas Medical Center
1998-1999 Obstetrician and Gynecologist, Saint Luke's Roosevelt Hospital Center, New York, NY
1999-2003 Director, Division of Reproductive Endocrinology, Saint Barnabas Medical Center
Other Professional Positions and Major Visiting Appointments:
1991-1992 Obstetrician and Gynecologist, Massachusetts Institute of Technology, Cambridge, MA
Internship and Residencies:
1986-1987 Intern in Obstetrics and Gynecology, New York Hospital, New York, NY
1987-1989 Resident in Obstetrics and Gynecology, New York Hospital
1989-1990 Chief Resident, Obstetrics and Gynecology, New York Hospital
1990-1992 Fellow, Reproductive Endocrinology, Brigham and Women's Hospital, Boston, MA
Licensure and Certification:
1987 New York State 172112
1990 Massachusetts 72477
1992 New Jersey MA58079
1994 Board Certified, American Board of Obstetrics and Gynecology
1995 Fellow, American College of Obstetricians and Gynecologists
1996 Fellow, American College of Surgeons
1997 Subspecialty Board Certified, Reproductive Endocrinology, American Board of Ob / Gyn
Awards and Honors:
1986 F.A. Davis Award, University of Pennsylvania
1998 Postgraduate teaching award, Saint Barnabas Medical Center
1998 Prize paper, Society for Assisted Reproductive Technology, 16th World Congress on Fertility and Sterility and 54th Annual Meeting of the American Society for Reproductive Medicine, San Francisco, CA
2002 Family Building Award, American Infertility Association
2004 Zenith Award, Resolve of New Jersey
Memberships in Professional Societies:
1986 American Medical Association
1987 American College of Obstetricians and Gynecologists
1989 American Society for Reproductive Medicine
1991 Society of Reproductive Endocrinologists
1991 American Association of Gynecologic Laparoscopists
1992 Academy of Medicine of New Jersey
1993 American Association for the Advancement of Science
1994 New Jersey Obstetrical and Gynecological Society
1994 New York Academy of Sciences
1996 American College of Surgeons
1999 American Institute for Ultrasound in Medicine
1998 Medical Society of the State of New York
1997 The Endocrine Society
1993-1995 Obstetrics and Gynecology
1998-2003 Fertility and Sterility
1. Sable, DB, Kaplan, FS. Osteoporosis: the estrogen dilemma. The University of Pennsylvania Orthopaedic Journal 2: 24-26, 1986.
2. Toth A, Sable DB, Hidvegi J. The use of an ambulatory infusion pump for the treatment of pelvic inflammatory disease.Am J Gynecol Health 1: 28-33,1990.
3. Sable DB, Yanushpolsky, EH, Fox, JH. Pelvic abscess following intrauterine insemination: a case report. Fertil Steril59(3): 679-680, 1993.
4. Sable DB, Yeh J. Growth Factor Receptor Messenger RNA Expression in Human Fetal Brain Regions. Obstetrics and Gynecology 86 (2): 240-247, 1995.
5. Rein MS, Sable DB, Jackson KV, Thomas P, Hornstein MD. Dexamethasone during ovulation induction for in vitro fertilization: a pilot study. Human Reproduction 11(2): 101-103, 1996.
6. Seaman EK, Telich-Vidal M, Sable DB. Effects of cancer treatment on fertility. Contemporary Ob/ Gyn 42(5): 31-52, 1997.
7. Munne S, Scott RT, Sable DB, Cohen J. First pregnancies after pre-conceptual testing of Robertsonian translocations of maternal origin. Fertil Steril 69(4): 675-681, 1998.
8. Munne S, Morrison L, Fung J, Marquez C, Weier U, Bahce M, Sable D, Grunfeld L, Schoolcraft B, Scott R, Cohen J. Spontaneous abortions are reduced after preconception diagnosis of translocations. J Assist Reprod Genet 15(5): 290-296, 1998.
9. Munne S, Magli C, Cohen J, Morton P, Sadowy S, Gianaroli L, Tucker M, Marquez C, Sable D, Ferraretti AP, Massey JB, Scott R. Positive outcome after preimplantation diagnosis of aneuploidy in human embryos. Hum Reprod1999 Sep; 14(9): 2191-2199.
10. Munne S, Escudero T, Sandalinas M, Sable D, Cohen J. Gamete segregation in female carriers of Robertsonian translocations. Cytogenet Cell Genet 2000; 90(3-4): 303-8.
11. Munne S, Cohen J, Sable D. Preimplantation genetic diagnosis for advanced maternal age and other indications. Fertil Steril 2002; 78(2): 234-236.
12. Cohen J, Alikani M, Sable D. Misleading press reports: another rebuttal. Reprod Biomed Online 2002 May-June; 4(3):261-262.
13. Munne S, Sandalinas M, Escudero T, Velilla E, Walmsley R, Sadowy S, Cohen J, Sable D. Improved implantation after preimplantation genetic diagnosis of aneuploidy. Reprod Biomed Online 2003 Jul-Aug; 7(1):91-97.
1. Sable DB, Yeh J. Detection of mRNA's encoding for receptors for fibroblast growth factor, transforming growth factor-beta, insulin, insulin-like growth factors I and II and epidermal growth factor in human fetal brain regions. Presented at the Conjoint Meeting of the American Fertility Society and the Canadian Fertility and Andrological Society, Montreal, Quebec, 1993.
2. Rein MS, Sable DB, Jackson KV, Thomas P, Hornstein MD. A randomized trial of dexamethasone during ovulation induction for in vitro fertilization (IVF). Presented at the 50th Annual Meeting of the American Fertility Society, San Antonio TX, 1994.
3. R. T. Scott, P. A. Bergh, D. B. Sable, S. D. Ernst, D. Ciggalione, M. Jackson, M. F. Raynault, M. Alikani, J. A. Garrisi, T. A. Ferrara, M. R. Drews. Unexplained implantation failure is much lower than previously reported. Presented at the 52nd Annual Meeting of the American Society for Reproductive Medicine, Boston MA, 1996.
4. Munne S, Magli C, Morton P, Sadowy S, Marquez C, Gianaroli L, Ferrareti P, Sable D, Scott R, Sandler B, Tucker M, Cohen J. Decrease in spontaneous abortions after genetic diagnosis of aneuploidy at the 8-cell stage. Presented at the 16th World Congress on Fertility and Sterility and 54th Annual Meeting of the American Society for Reproductive Medicine, San Francisco, CA, 1998.
5. Munne S, Magli C, Jones A, Gianaroli L, Sable DB, Cohen J. Babies born after embryo biopsy and aneuploidy testing. Presented at the 56th Annual Meeting of the American Society for Reproductive Medicine, San Diego CA, 2000.
6. Barritt JA, Tomkin G, Sable DB, Cohen J. Effects of cytoplasmic transfer on embryo viability are post-genomic. Presented at the 57th Annual Meeting of the American Society for Reproductive Medicine, Orlando FL, 2001.
7. Chen SH, Escudero T, Cekleniak NA, Sable DB,Garrisi MG, Munne S. Maternal balanced translocation is a risk factor for poor response to ovarian stimulation. Presented at the 58th Annual Meeting of the American Society for Reproductive Medicine, Seattle WA, 2002.
8. Chen SH, Mack CK, Cekleniak NA, Garrisi MG, Schramm AT, Sable DB. GnRH antagonists and poor responders: is there hope after a failed microdose agonist flare cycle? Presented at the 58th Annual Meeting of the American Society for Reproductive Medicine, Seattle WA, 2002.